Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2026-01-04 @ 12:15 AM
Study NCT ID:
NCT01125566
Status:
COMPLETED
Last Update Posted:
2019-07-18
First Post:
2010-05-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Sponsor:
Boehringer Ingelheim
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
1200.75
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None